← Back to screener

CAPRICOR THERAPEUTICS, INC. CAPR

Rank #2464 · Nasdaq · $0.4B market cap
Audited by Rose, Snyder & Jacobs LLP, no going-concern flag in the latest filing.
Score
16.0
P/E
-9.1
P/B
16.35
ROE
-179.0%
Op. Margin
-191.1%
Debt Ratio
111%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -9.1x, P/B 16.35x. Ranks in the top 86% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -179.0%. Ranks in the top 94% of the universe.

Safety ★★★☆☆
Average

Debt ratio 111%. Ranks in the top 43% of the universe.

Growth ★☆☆☆☆
Poor

Revenue decline of 11.5% year over year. Ranks in the top 85% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$-0.0B-464.6-72794
2012$0.0B$-0.0B$-0.0B$-0.0B-361.7-10737
2013–$-0.0B$-0.0B$0.0B––
2014$0.0B$-0.0B$-0.0B$0.0B-1371.7124
2015$0.0B$-0.0B$-0.0B$-0.0B-125.7-3717
2016$0.0B$-0.0B$-0.0B$-0.0B-228.6-274
2017$0.0B$-0.0B$-0.0B$-0.0B-424.6-2205
2018$0.0B$-0.0B$0.0B$-0.0B-482.4-126
2019$0.0B$-0.0B$-0.0B$0.0B-917.041
2020$0.0B$-0.0B$-0.0B$0.0B-769.593
2021$0.0B$-0.0B$-0.0B$0.0B-4412.694
2022$0.0B$-0.0B$-0.0B$0.0B-8549.935
2023$0.0B$-0.0B$-0.0B$0.0B-1163.9122
2024$0.0B$-0.0B$-0.0B$0.0B-95.6307
2025$0.0B$-0.0B$-0.0B$0.0B-191.1111

← See the full screener